Category: Stock Market

Artrya Ltd (ASX: AYA) shares are starting the week with a bang.

In morning trade, the ASX AI share is up over 11% to $3.85.

Why is this ASX AI share jumping?

Investors have been bidding the company’s shares higher today after it secured its second customer in the United States.

According to the release, Artrya, which is a medical technology company commercialising its Salix AI-powered cloud platform, has signed a commercial agreement with Northeast Georgia Health System.

Management believes this marks another significant milestone in the company’s accelerating U.S. expansion strategy.

The Salix AI-powered cloud platform is used for the near real time, point of care assessment and management of coronary artery disease.

The release notes that the three-year commercial agreement has a minimum value of US$0.3 million, with additional fee-per-scan revenue from the Salix Coronary Plaque module and, following FDA clearance, the Salix Coronary Flow module.

The Salix platform will be rolled out across Northeast Georgia Health System’s network of hospitals and used by its cardiology group, Georgia Heart Institute.

Commenting on the news, the ASX AI share’s co-founder and CEO, John Konstantopoulos, said:

We are proud to secure our second U.S. commercial customer through this three-year commercial agreement with Northeast Georgia Health System, a respected leader in patient care across the U.S. Southeast. This builds our longstanding partnership to validate Salix in their workflow, and we are excited to roll out Salix across the Northeast Georgia Health System network.

We remain on track to convert all three U.S. foundation partners to commercial customers this year, where our new Customer Success team is already playing a leading role in integration and support.

Georgia Heart Institute’s chief cardiology officer, Mudassar Ahmed, MD, MBA, spoke positively about the deal, commenting:

The Salix platform will now go live in our clinical workflow, which represents an important step forward in how we deliver cardiovascular care. At Georgia Heart Institute, we are committed to adopting technologies that not only enhance diagnostic precision but also transform the patient journey. Through our work during the past two years, we have seen that Salix can bring a new dimension to our practice by supporting earlier identification of risk and enabling more proactive treatment strategies.

To support its growing U.S. customer base and anticipated expansion, the ASX AI share has established a customer success team in Atlanta. It notes that this team will serve as a technology and support hub, providing technical integration expertise, clinician engagement, and comprehensive customer support on the ground.

The post Why is this ASX AI share jumping 11% today? appeared first on The Motley Fool Australia.

More reading

• These 2 ASX small-cap shares have big potential for returns

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The APA Group (ASX: APA) share price is in focus today after S&P Global Ratings reaffirmed its BBB credit rating and improved APA’s debt threshold, enabling over $1 billion in extra growth funding.

What did APA Group report?

• S&P affirmed APA’s BBB (stable) long-term credit rating
• S&P lowered APA’s downside FFO to Debt threshold from 9.5% to 8.5%
• The modification increases debt capacity by more than $1 billion
• APA maintains stable and predictable cash flows
• The change strengthens APA’s ability to fund future growth projects

What else do investors need to know?

The adjustment from S&P recognises APA’s consistent cash generation and solid financial management. By lowering the downside threshold, APA can now take on additional debt to pursue expansion across its $27 billion portfolio of infrastructure assets.

APA supplies about half of Australia’s domestic gas through its 15,000 kilometres of pipelines and operates a mix of gas, electricity, wind, and solar assets nationally. This strengthened balance sheet supports the company’s strategy of securing Australia’s energy future.

What did APA Group management say?

CEO and Managing Director Adam Watson said:

It is pleasing to see S&P acknowledge the high-quality of our ongoing cashflows. S&P’s modification of our FFO to debt downside threshold is significant, providing more than $1 billion in additional funding capacity from our existing balance sheet.

We have strong momentum in the delivery of our growth strategy and remain focussed on efficient and prudent capital allocation to capture value from the most attractive long-term opportunities for APA securityholders. This ratings modification will provide further funding support for our attractive growth projects.

What’s next for APA Group?

APA is expected to use this enhanced debt capacity to fund new projects across its key energy infrastructure networks. The company remains focused on efficient investment and pursuing growth opportunities that can deliver value for securityholders.

As the transition to renewable energy accelerates and demand for reliable energy infrastructure grows, APA aims to maintain its strong financial position to support the nation’s evolving energy needs.

APA Group share price snapshot

APA Group shares have risen 27% over the past 12 months, outperforming the S&P/ASX 200 Index (ASX: XJO) which has increased 2% over the same period. 

View Original Announcement

The post APA Group gains $1bn extra funding capacity after S&P credit rating change appeared first on The Motley Fool Australia.

More reading

• DigiCo Infrastructure REIT appoints new CEO and sets strategic growth path
• Telix Pharmaceuticals updates investors as first patient is dosed in Phase 3 prostate cancer trial
• National Storage REIT agrees to $4bn Brookfield-GIC buyout: What it means for investors
• Corporate Travel Management and Boss Energy shares dumped from ASX 200
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Apa Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Shares in National Storage REIT (ASX: NSR) are trading higher on Monday after the company’s board said it would back a private equity-led takeover for the company.

National Storage, in late November, was forced to reveal that it was in takeover talks with Brookfield Property Group and GIC Investments after an article alluding to the deal was published by The Australian.

Bid now recommended by board

At the time, the then potential bid was “non-binding, indicative and conditional”; however, the NSR board on Monday said it would back the bid in the absence of a superior offer.

As the company said in a statement to the ASX:

The board of NSR unanimously recommends that NSR securityholders vote in favour of the transaction, in the absence of a superior proposal and subject to the independent expert concluding in the independent expert’s report (and continuing to conclude) that the transaction is in the best interests of NSR securityholders. Subject to the same qualifications, each NSR director intends to vote all NSR stapled securities controlled or held by them in favour of the transaction resolutions.

National Storage chair Anthony Keane said the board believed the transaction provided an attractive valuation and certainty for shareholders.

As he said:

The offer from the consortium follows a number of earlier offers and a period of negotiation. The decision to recommend this offer follows extensive work by the NSR board and its advisers to assess the fundamental value of NSR and its medium-to-long term prospects. Accordingly, the NSR board is unanimous in its recommendation that the transaction represents a compelling outcome for NSR securityholders.  

Shareholders in NSR will receive $2.86 per share, which will be reduced by 6 cents per share if the company pays out a dividend of that amount before the deal goes through.

Regulatory sign-off needed

The deal is subject to approval by the Foreign Investment Review Board and the New Zealand Office of Overseas Investment.

It will also need to be voted on by National Storage shareholders, with the meeting at which this vote is to take place likely to be held in April.

The deal is also subject to a break fee of $40 million should the consortium or National Storage decide to pull out of the transaction.

An independent expert’s report on the deal will now be completed and provided to shareholders before they are due to vote on the transaction.

National Storage shares were changing hands for $2.80 on Monday morning.

The post National Storage shares up as board recommends takeover bid appeared first on The Motley Fool Australia.

More reading

• National Storage REIT agrees to $4bn Brookfield-GIC buyout: What it means for investors
• These two takeover targets are still trading below their potential bid prices
• 3 ASX 200 shares smashing the benchmark this week
• This ASX storage REIT’s shares surge as takeover talks confirmed
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX) shares are falling on Monday.

In morning trade, the ASX biotech stock is down 1% to $14.65.

What’s going on with Telix shares?

Telix shares are falling today despite the announcement from the radiopharmaceuticals company relating to its ProstACT Global Phase 3 study.

The company notes that ProstACT Global study is an international, multi-centre trial in two parts. Part 1 is a safety and dosimetry lead-in with 30 patients, whereas Part 2 is a 2:1 randomised global expansion with an overall target enrolment of approximately 490 patients.

The study is evaluating its lead prostate cancer therapy candidate TLX591 in patients with metastatic castration resistant prostate cancer (mCRPC).

According to the release, the first patient was dosed at the Australian Prostate Centre (APC) in Melbourne, Australia.

Management is optimistic about the future of TLX591. It highlights that it is the first phase 3 trial to combine a PSMA targeted radio antibody drug conjugate (rADC) therapy administered together with the standard of care versus the standard of care alone.

What’s next?

Telix has previously agreed with US Food and Drug Administration (FDA) that it will submit Part 1 data to enable clearance to expand Part 2 of the trial to U.S. sites.

A public disclosure of preliminary results from Part 1 of the study will be aligned to engagement with the FDA.

The study is also approved to commence in China, Japan, Singapore, South Korea, Turkey, and the United Kingdom. In addition, as part of the further global expansion of the trial, the company will file a clinical trial application (CTA) with the European Medicines Agency (EMA) to enable expansion into EU sites.

Commenting on the news, Telix’s group chief medical officer, Dr David N Cade, said:

Dosing the first patient into Part 2 of the randomized treatment expansion of ProstACT Global trial is a significant milestone for Telix’s late-stage prostate cancer therapeutics pipeline. We look forward to presenting the preliminary data from Part 1 of the study to the FDA and EMA in the coming months.

Should you invest?

While it has not yet responded to today’s news, the team at Bell Potter is bullish on Telix shares.

It currently has a buy rating and $23.00 price target on them, which implies potential upside of over 50% for investors based on its last close price.

The post Telix shares fall despite ‘significant milestone’ appeared first on The Motley Fool Australia.

More reading

• Telix Pharmaceuticals updates investors as first patient is dosed in Phase 3 prostate cancer trial
• These ASX innovators could be the market’s next big winners
• These are the 10 most shorted ASX shares
• Build significant wealth with these ASX growth shares over the next 10 years
• These are the 10 most shorted ASX shares

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Regis Resources Ltd (ASX: RRL) shares are edging lower today.

Shares in the S&P/ASX 200 Index (ASX: XJO) gold stock closed on Friday trading for $7.09. In morning trade on Monday, shares are changing hands for $7.08 apiece, down 0.1%.

For some context, the ASX 200 is down 0.2% at this same time.

With today’s intraday moves factored in, Regis Resources shares remain up a remarkable 174.5% year to date, smashing the 5.1% gains delivered by the benchmark index.

The ASX 200 gold stock has been an obvious beneficiary of the soaring gold price. The yellow metal is currently trading for US$4,198 per ounce, up 60% in 2025. But the miner has hardly been sitting on its laurels.

Here’s what the company reported this morning.

Regis Resources shares eyeing growth prospects

The ASX gold miner has released its twice-yearly exploration update across its Duketon and Tropicana projects, both located in Western Australia.

Building longer-term support for Regis Resources shares, the miner said that over the half year it continued advancing priority underground and open pit targets, improving its geological confidence across key growth areas.

Management said they are now assessing longer-term opportunities within both operations, noting the company is evaluating and testing 100 exploration prospects and projects at varying stages of development.

Among the highlights of the past six months of exploration, Regis said strong drilling results at its Garden Well Underground project confirmed the continuity of mineralisation outside of the current mine designs. The miner said these results support ongoing assessment of deeper down-plunge extensions at the prospect.

And at the Rosemont Stage 3 Underground gold mine, Regis said its resource definition and extensional drilling continued to intersect multiple zones of high-grade mineralisation. This has extended the system some 300 metres beyond current designs and strengthened the medium-term underground growth potential at the mine.

What did management say?

Commenting on the exploration program that should support Regis Resources shares longer-term, CEO Jim Beyer said, “Our exploration teams continue to deliver solid progress across the business.”

He noted, “The work completed over the past six months has strengthened our understanding of the underground growth pipeline at Duketon and confirmed further extensions at Tropicana.”

Beyer concluded:

The team’s systematic approach is building confidence by providing a steady flow of opportunities to support future studies, Reserve conversion and long-term mine life planning. We are very encouraged by the results to date and see ongoing potential across our portfolio as drilling continues into the second half of FY 2026.

The post Regis Resources shares are up 175% in 2025. Here are the latest ‘very encouraging’ gold exploration results appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Friday
• Up 170% this year, does Macquarie rate Regis Resources shares a buy, hold or sell?
• Here are the top 10 ASX 200 shares today
• Why Breville, Flight Centre, Navigator Global, and Regis Resources shares are racing higher
• Up 202% in a year, here’s why Regis Resources shares are rocketing again today

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The companies that are in and out of key ASX indices have been announced, with the Gina Rinehart-backed Lynas Rare Earths Ltd (ASX: LYC) and Washington H. Soul Pattinson and Company Ltd (ASX: SOL) soon to join the S&P/ASX 50 Index (ASX: XFL).

The most recent rebalance of the ASX indices is set to take effect from December 22, with the additions and exclusions to each index important for funds that look to track those indices.

As such, an inclusion can be a boon for shareholders, while an exclusion can put downward pressure on a company’s share price performance.

With Lynas and Soul Patts to be included in the ASX 50, two companies, Amcor Plc (ASX: AMC) and Mirvac Group (ASX: MGR), will be removed.

China moves spur interest in Lynas

Lynas shares have been trading between $13 and $16 for the past month or so, after surging to a 12-month high of $21.96 in mid-October at a time when China flagged extra export controls on key rare earths elements.

The shares are still well up on the 12-month lows of $6.16, and Macquarie recently issued a research note maintaining its outperform rating for the stock, with a 12-month price target of $17. The shares closed Friday’s session at $14.14.

As for the S&P/ASX 100 Index (ASX: XTO), vehicle dealership owner Eagers Automotive Ltd (ASX: APE) will be included in the next rebalance, as will Capricorn Metals Ltd (ASX: CMM).

The $7.57 billion Eagers, in recent months, announced a major capital raise at $21 per share to help pay for its $1.04 billion 65% buyout of CanadaOne Auto Group, with the shares continuing to trade well above that level, last changing hands for $26.84.

Analysts have looked kindly on the CanadaOne purchase, with Macquarie in early November saying the “acquisition of CanadaOne provides a platform for further North American inorganic growth, in what is a highly fragmented market”.

At the time, Macquarie had a price target of $29.98 on Eagers stock.

As for Capricorn Metals, its shares are up more than 100% over the past 12 months, during which time it acquired its Mt Gibson gold project where it has grown the mineral resource estimate to 4.5 million ounces of contained gold.

The company also recently acquired Warriedar Resources for an equity value of $188 million.

To make way for Eagers and Capricorn, Reece Ltd (ASX: REH) and Reliance Worldwide Corporation Ltd (ASX: RWC) will be removed from the ASX 100.

There will be no changes to the S&P/ASX 20 Index (ASX: XTL) this time around.

The post See which companies have just been added to key ASX indices appeared first on The Motley Fool Australia.

More reading

• Guess which ASX mining stock was just promoted to the S&P/ASX 50?
• 2 ASX giants to buy for decades of growth and dividends
• Could this undervalued ASX stock be your ticket to millionaire status?
• Bell Potter names the best ASX 200 shares to buy in December
• 3 top ASX dividend share buys for passive income in December

Motley Fool contributor Cameron England has positions in Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Lynas Rare Earths Ltd. The Motley Fool Australia has positions in and has recommended Amcor Plc, Macquarie Group, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has recommended Eagers Automotive Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

DigiCo Infrastructure REIT (ASX: DGT) shares are starting the week in the red.

In morning trade, the ASX AI share is down 1% to $2.48.

What’s going on with this ASX AI share?

Investors have been selling the data centre operator’s shares today after broad weakness in the tech sector overshadowed the announcement of the appointment of its new CEO.

According to the release, the company has appointed Michael Juniper as the CEO of the DigiCo Infrastructure REIT and managing director of digital infrastructure for HMC Capital Ltd (ASX: HMC), with immediate effect.

The release notes that Juniper brings more than two decades of experience in digital infrastructure.

He was a founding executive and deputy CEO at AirTrunk, where he helped build one of Asia-Pacific’s leading hyperscale platforms. This includes expanding AirTrunk into major Asian markets including Japan, Singapore, Malaysia and Hong Kong, and partnering with the world’s largest cloud and technology companies.

The ASX AI stock revealed that the decision to appoint Juniper as CEO followed his appointment as a senior executive and director in September.

It highlights that his experience, relationships, and track record in this sector make him ideally placed to lead the company.

Commenting on his appointment, Michael Juniper said:

I am honoured to assume the role of Chief Executive Officer of DGT. DGT is uniquely positioned as Australia’s sovereign digital infrastructure platform, with strong foundations and a high-quality global portfolio. Demand from cloud, AI and GPU-led workloads is accelerating, and DGT is building a future-ready organisation that is required to support these next-generation requirements.

Innovative energy solutions are becoming critical differentiators for our customers, and DGT is uniquely placed to potentially leverage HMC’s broader energy and transition platform to deliver long-term power certainty and sustainable growth at scale across cloud, AI and enterprise workloads. I look forward to working closely with the Board, our customers, government and our talented team as we create value for our securityholders in our next phase of growth.

The ASX AI share’s chair, Joseph Carrozzi AM, was pleased with the appointment.

He believes that Juniper will able to deliver on the next phase of the DigiCo Infrastructure REIT’s strategy. Carrozzi said:

We are pleased with the appointment of Michael to lead the next phase of DGT’s strategy. His exceptional track record in building hyperscale platforms across the region makes him uniquely qualified to guide DGT through the growth ahead. We thank Chris for his leadership and contribution to DGT, having led the company through its IPO and foundation period as a listed entity. We look forward to his continued contribution in this important new government-facing role.

The post What’s going on with this ASX AI share on Monday? appeared first on The Motley Fool Australia.

More reading

• DigiCo Infrastructure REIT appoints new CEO and sets strategic growth path
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• What is Bell Potter’s view on REITs?
• 3 ASX shares I’d buy with $20,000 today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended HMC Capital. The Motley Fool Australia has recommended HMC Capital. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you are wanting some exposure to the booming gold price, then read on!

That’s because the team at Bell Potter has identified as ASX 200 gold stock that it believes could rise very strongly from current levels.

Which ASX 200 gold stock?

The gold miner that Bell Potter is bullish on this month is Catalyst Metals Ltd (ASX: CYL).

Catalyst Metals is a mid-tier Australian gold miner and developer with 100% ownership of two key projects. These are the Plutonic Gold Operation in Western Australia and the Bendigo Gold Project in Victoria. Bell Potter highlights that these assets are located in highly prospective, low sovereign risk jurisdictions.

What is the broker saying?

Bell Potter has resumed coverage on the ASX 200 gold stock and is feeling very positive due to its 10-year growth strategy. It explains:

We see CYL as an emerging mid-tier gold producer in Western Australia, operating within a stable, low-risk jurisdiction. The Company is embarking on a 10-year growth strategy for its Plutonic Gold Operations (PGO), targeting a 200kozpa production rate. This will be achieved by developing five mines under a hub-and-spoke model and leveraging latent processing capacity at the 1.8Mtpa processing plant.

Production is anticipated to double from 100kozpa in FY26 to 200kozpa from FY29 (~28% CAGR), due to the forecasted increase in tonnes and grade (3.13g/t vs 2.27g/t in FY26) as higher grade mines come online. CYL remains debt free with no gold hedging contracts, allowing full exposure to gold price upside, particularly attractive in the current gold bull market.

Big potential returns

According to the release, the broker has put a buy rating and $9.30 price target on the ASX gold stock.

Based on its current share price of $6.55, this implies potential upside of 42% for investors over the next 12 months.

Commenting on its buy recommendation, Bell Potter said:

We recommence coverage of CYL with a BUY recommendation and a $9.30/sh TP. CYL is considered undervalued against its peers (EV/EBITDA 5.3x, FY26E/27E FCF yield of 1.5% to 7.1%). We view CYL as derisking the Plutonic gold hub with a clear line of sight to a 200kozpa steady state (FY29). Execution on the plan (five mines feeding an underutilised 1.8Mtpa plant) and Reserve growth towards >2Moz are viewed as the key drivers of multiple re- ratings and margin expansion.

The post Why this emerging ASX 200 gold stock could rise 40%+ appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Monday
• Here are the top 10 ASX 200 shares today
• Morgans names 3 ASX 200 shares to buy in November

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The DigiCo Infrastructure REIT (ASX: DGT) share price drew attention today as the company announced Michael Juniper as its new CEO. Juniper’s appointment comes alongside a strategic management reshuffle and a continued focus on data centre expansion to meet rising demand for cloud and AI services.

What did DigiCo Infrastructure REIT report?

• Michael Juniper appointed Chief Executive Officer and Managing Director, Digital Infrastructure
• Chris Maher to transition to Managing Director, Group Head of Government & Strategic Programs for HMC Capital
• Ongoing development of next-generation data centre campuses in Australia and North America
• Portfolio of 13 data centres with 76MW installed and a 156MW development pipeline
• Strong focus on energy solutions to support future growth in cloud and AI services

What else do investors need to know?

DigiCo Infrastructure REIT highlighted the growing importance of government and regulatory engagement as policy on data, AI, and energy evolves. The transition of Chris Maher into a specialist government role is intended to strengthen DigiCo’s capabilities in navigating these changes.

Michael Juniper brings a notable track record, previously helping build AirTrunk into Asia-Pacific’s largest hyperscale platform. His appointment is expected to guide DigiCo through its next growth phase, particularly as demand for digital infrastructure and data capacity increases.

What did DigiCo Infrastructure REIT management say?

Michael Juniper, CEO and Managing Director, said:

I am honoured to assume the role of Chief Executive Officer of DGT. DGT is uniquely positioned as Australia’s sovereign digital infrastructure platform, with strong foundations and a high-quality global portfolio. Demand from cloud, AI and GPU-led workloads is accelerating, and DGT is building a future-ready organisation that is required to support these next-generation requirements.

What’s next for DigiCo Infrastructure REIT?

Under its new leadership, DigiCo plans to continue expanding its network of data centres across Australia and North America. The trust will further develop its capabilities in energy solutions, aiming to provide sustainable, long-term infrastructure for customers operating cloud and AI workloads.

The company is also prioritising close engagement with government and regulatory bodies to adapt to ongoing changes in the digital and energy sectors. This is expected to help DigiCo maintain momentum during its next phase of strategic growth.

DigiCo Infrastructure REIT share price snapshot

DigiCo Infrastructure REIT shares have declined 44% in the past 12 months, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen around 3% over the same period.

View Original Announcement

The post DigiCo Infrastructure REIT appoints new CEO and sets strategic growth path appeared first on The Motley Fool Australia.

More reading

• What’s going on with this ASX AI share on Monday?
• Telix Pharmaceuticals updates investors as first patient is dosed in Phase 3 prostate cancer trial
• National Storage REIT agrees to $4bn Brookfield-GIC buyout: What it means for investors
• Corporate Travel Management and Boss Energy shares dumped from ASX 200
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after the company announced the first patient has been dosed in Part 2 of its ProstACT Global Phase 3 trial for treating advanced prostate cancer. The company also confirmed plans for a key Part 1 data readout and further regulatory engagement.

What did Telix Pharmaceuticals report?

• First patient dosed in ProstACT Global Phase 3 trial (randomised treatment expansion, Part 2)
• Part 2 to enrol about 490 patients across Australia, New Zealand, and Canada
• Approval granted to also commence trial sites in China, Japan, Singapore, South Korea, Türkiye, and the UK
• Part 1 data to be submitted to the US FDA, aligning public results disclosure
• No newly reported revenue or financial figures in this update

What else do investors need to know?

ProstACT Global is the first Phase 3 trial to test a PSMA-targeted radio antibody drug combined with standard-of-care therapies versus standard-of-care alone for metastatic castration-resistant prostate cancer. The global rollout is accelerating, with applications underway to expand into European sites.

The company highlights potential patient benefits, including different targeting and fewer side effects such as kidney toxicity and dry mouth compared to current radioligand therapies. The clinical trial’s expansion signals Telix’s growing international ambition, including approaching both US and European regulators for further approvals.

What did Telix Pharmaceuticals management say?

Dr. David N. Cade, Group Chief Medical Officer, said:

Dosing the first patient into Part 2 of the randomized treatment expansion of ProstACT Global trial is a significant milestone for Telix’s late-stage prostate cancer therapeutics pipeline. We look forward to presenting the preliminary data from Part 1 of the study to the FDA and EMA in the coming months.

What’s next for Telix Pharmaceuticals?

Telix plans to submit Part 1 data to the FDA to enable US site participation in the clinical trial and expects to share preliminary results publicly in line with its regulatory strategy. In parallel, the company is seeking further expansion into Europe and other international markets.

With global recruitment underway and regulatory milestones ahead, Telix aims to strengthen its late-stage oncology pipeline and broaden its impact for patients with advanced prostate cancer.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix Pharmaceuticals shares have declined 40%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 3% over the same period.

View Original Announcement

The post Telix Pharmaceuticals updates investors as first patient is dosed in Phase 3 prostate cancer trial appeared first on The Motley Fool Australia.

More reading

• National Storage REIT agrees to $4bn Brookfield-GIC buyout: What it means for investors
• Corporate Travel Management and Boss Energy shares dumped from ASX 200
• 5 things to watch on the ASX 200 on Monday
• 6 ASX shares including Ora Banda and Aussie Broadband ascend into ASX 200
• Guess which ASX mining stock was just promoted to the S&P/ASX 50?

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.